Blood glucose was measured using an adaption of the hexokinase-glucose-6-phosphate dehydrogenase method on a Siemens Dimension analysers (RxL and EXL).
Plasma insulin concentrations were measured using a DAKO ELISA (DAKO Ltd., Denmark House, Angel Drove, Ely, Cambs, UK) according to the manufacturer’s instructions.
Lipids: measurements of total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides were performed enzymatically on a Dimension RXL system (Dade Behring) using reagents and calibrants supplied by the manufacturer.
hsCRP: was measured in plasma samples by laser immunonephelometry (Dade Behring).
ADMA: was measured by stable isotope dilution electrospray tandem mass spectrometry, as previously described [24 (link)].
HbA1c: samples were centrally on a TOSOH G7 analyzer, using high-performance liquid chromatography and absorbance change detection and Diabetes Control and Complications Trial (DCCT) aligned methods.
Urinary albumin and creatinine: were measured centrally as previously described [25 (link)].
Plasma insulin concentrations were measured using a DAKO ELISA (DAKO Ltd., Denmark House, Angel Drove, Ely, Cambs, UK) according to the manufacturer’s instructions.
Lipids: measurements of total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides were performed enzymatically on a Dimension RXL system (Dade Behring) using reagents and calibrants supplied by the manufacturer.
hsCRP: was measured in plasma samples by laser immunonephelometry (Dade Behring).
ADMA: was measured by stable isotope dilution electrospray tandem mass spectrometry, as previously described [24 (link)].
HbA1c: samples were centrally on a TOSOH G7 analyzer, using high-performance liquid chromatography and absorbance change detection and Diabetes Control and Complications Trial (DCCT) aligned methods.
Urinary albumin and creatinine: were measured centrally as previously described [25 (link)].
